Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 23

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 23
---
 are confidential. The settlement has no material impact on Takeda’s condensed interim consolidated statements of profit or loss for the nine-month period ended December 31, 2024.

<div align='center'>14</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

2. Condensed Interim Consolidated Financial Statements [IFRS] and Major Notes

(1) Condensed Interim Consolidated Statements of Profit or Loss

|                                                                                  |     | JPY (millions, except per share data) 
 Nine-month Period Ended December 31,  |       2023 |     |     |       2024 |
|:---------------------------------------------------------------------------------|:----|:--------------------------------------|-----------:|:----|:----|-----------:|
| Revenue                                                                          |     |                                       |  3,212,893 |     |     |  3,528,152 |
| Cost of sales                                                                    |     |                                       | -1,044,177 |     |     | -1,198,139 |
| Selling, general and administrative expenses                                     |     |                                       |   -768,585 |     |     |   -808,900 |
| Research and development expenses                                                |     |                                       |   -534,068 |     |     |   -514,220 |
| Amortization and impairment losses on intangible assets associated with products |     |                                       |   -507,003 |     |     |   -440,158 |
| Other operating income                                                           |     |                                       |     10,768 |     |     |     16,227 |
| Other operating expenses                                                         |     |                                       |   -145,685 |     |     |   -165,444 |
| Operating profit                                                                 |     |                                       |    224,144 |     |     |    417,518 |
| Finance income                                                                   |     |                                       |     46,101 |     |     |     27,805 |
| Finance expenses                                                                 |     |                                       |   -172,663 |     |     |   -159,741 |
| Share of profit (loss) of investments accounted for using the equity method      |     |                                       |      2,731 |     |     |     -3,199 |
| Profit before tax                                                                |     |                                       |    100,313 |     |